Development of an intranodal administration method

Features

(1) The amount of anticancer drug required to treat one metastatic lymph node is 1/1,000 to 1/10,000 of the systemic dose.
(2) The drug can be administered into the lymph node under ultrasound guidance.
(3) An international patent has been filed for the solvent of the administered drug.

Targeted Application(s)/Industry

1. Treatment and prophylactic therapy of affiliated lymph nodes in head and neck cancer, breast cancer, etc.
2. Pharmaceutical companies aiming to develop drugs by drug repositioning and generics
3. Medical device manufacturers aiming to develop a dosing system